Printer Friendly

ORGANOGENESIS 4TH QUARTER APLIGRAF SALES SURPASS 4000 UNITS.

Organogenesis Inc. (AMEX:ORG) has reported that US commercial sales of lead product Apligraf reached 4084 units for the fourth quarter of 2000, up from 3232 units for the previous quarter. This was the largest quarter-to-quarter increase to date. The fourth quarter included record monthly sales in both October and November. Apligraf sales in December were impacted by holidays, but still reached 1209 units. Apligraf is marketed by Novartis Pharmaceuticals Corporation.

US Commercial Unit Sales of Apligraf

Time-----Quarter

1Q99-----1585

2Q99-----1755

3Q99-----1817

4Q99-----2192

1Q00-----2555

2Q00-----2814

3Q00-----3232

4Q00-----4084

"We are clearly seeing acceleration in the growth of Apligraf sales," said Philip Laughlin, president and chief executive officer. "We attribute this to gaining the diabetic foot ulcer indication, expanding coverage under Medicare and the increased sales and marketing support behind the product."

Organogenesis is the only tissue-engineering company to have developed and gained FDA approval for a mass-produced product containing living human cells. The company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Lead product Apligraf - a cellular, bi-layered skin substitute - is approved and marketed for the treatment of venous leg ulcers and diabetic foot ulcers; Novartis Pharma AG has global Apligraf marketing rights. The Organogenesis research pipeline includes the VITRIX living dermal replacement product, a coronary vascular graft and a liver assist device.

For more information, call 781-575-0775.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:sales information
Comment:ORGANOGENESIS 4TH QUARTER APLIGRAF SALES SURPASS 4000 UNITS.(sales information)
Publication:Biotech Financial Reports
Article Type:Brief Article
Geographic Code:1USA
Date:Feb 1, 2001
Words:223
Previous Article:GENESIS HEALTH VENTURES REPORTS $2.4 BILLION IN REVENUE.
Next Article:FORBES MEDI-TECH REPORTS 1ST QTR NET LOSS OF $0.17 PER SHARE.
Topics:


Related Articles
Novartis given approval by FDA to market Apligraf for the treatment of venous leg ulcers
FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.
Organogenesis Apligraf approved by HCFA for payment.
Organogenesis begins clinical trial of living skin replacement to promote wound healing.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |